Abstract
There are limited real-world data on the treatment practices and healthcare resource utilization associated with chronic lymphocytic leukemia (CLL) in Japan. In this study (CLIMBER-DBR), we performed retrospective analyses of the Japanese Medical Data Vision database, and extracted data for 2562 patients with newly diagnosed CLL (CLL-1 cohort) and 930 patients receiving CLL treatment (CLL-2 cohort) registered between March 1, 2013 and February 28, 2018. The median follow-up in the CLL-1 cohort was 721 (quartile 1-3: 363-1267) days and the median time to initial (first-line) treatment was 1331 (quartile 1-3: 189-not reached) days. In the CLL-2 cohort, the most frequently used regimens were fludarabine alone (17.7%), cyclophosphamide alone (13.7%), and bendamustine/rituximab (8.2%). The median (quartile 1-3) times to second-line and third-line treatments were 1066 (273-not reached) and 1795 (631-not reached) days, respectively. The CLIMBER-DBR was the first database research study to assess current treatment practices for CLL in Japan, where the treatment patterns were driven by the approval/reimbursement status of drugs in the study period. Our study provides an important benchmark for future studies of CLL in Japan.
References
Sep 30, 2000·Pathology International
Jul 28, 2012·International Journal of Molecular Sciences·Kiyoshi KikuchiEiichiro Tanaka
Nov 20, 2013·British Journal of Haematology·Dai ChiharaKeitaro Matsuo
Dec 4, 2015·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Jun-Ichi SuzukiRyuichi Morishita
Dec 8, 2015·The New England Journal of Medicine·Jan A BurgerUNKNOWN RESONATE-2 Investigators
Dec 23, 2015·American Journal of Hematology·Kanti R Rai, Preetesh Jain
Nov 20, 2016·British Journal of Haematology·Anthony MatoJeff P Sharman
Nov 22, 2017·Expert Review of Hematology·Tamar TadmorIwona Hus
Feb 15, 2018·PharmacoEconomics Open·Jörg MahlichAkiko Tsubota
Mar 16, 2018·Blood·Michael HallekThomas J Kipps
Oct 22, 2018·Cancer·Erlene K SeymourCharles A Schiffer
Jan 18, 2019·International Journal of Hematologic Oncology·John N Allan, Richard R Furman
May 31, 2019·Cancer Medicine·Shaum M KabadiKeith L Davis
Sep 13, 2019·American Journal of Hematology·Talha MunirJennifer A Woyach
Apr 8, 2020·International Journal of Hematology·Junji Suzumiya, Jun Takizawa